Literature DB >> 2438673

Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer.

J Tremblay, G Frenette, R R Tremblay, A Dupont, M Thabet, J Y Dube.   

Abstract

We have studied the mode of excretion of three prostatic secretory proteins, namely acid phosphatase (PAP), prostate-specific antigen (PSA) and beta-inhibin, in the urine of normal adult men, and we have determined the urinary levels of these proteins in men with benign prostatic hypertrophy (BPH) or adenocarcinoma. The output of the three proteins was highly variable during the day. In order to minimize these variations, 24-hour urine samples were collected thereafter. Our study showed that PAP concentrations in 50% of men with or without symptomatic BPH were similar to those of normal young men. In the remaining 50%, PAP was undetectable. In contrast, average PSA and beta-inhibin concentrations were higher in patients with BPH than in young men (p less than 0.05). The three markers were decreased or nondetectable in about half of the patients with untreated prostatic cancer. This phenomenon was even more pronounced in patients receiving hormonal treatment (castration or diethylstilbestrol). However, some of these patients still excreted normal amounts of PAP, PSA, and beta-inhibin. Urinary and serum PAP levels showed no correlation. These results indicate that urinary prostatic markers provide an easy means to study the behavior of the primary prostatic tumor. This information may be of potential value since it is not obtained with serum markers which originate mostly from metastatic cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438673     DOI: 10.1002/pros.2990100306

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Objective non-intrusive markers of sperm production and sexual activity.

Authors:  Thilee Sivananthan; Franz Bathur; Mark Jimenez; Ann Conway; Amanda Idan; David Handelsman
Journal:  Asian J Androl       Date:  2012-04-23       Impact factor: 3.285

2.  The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor.

Authors:  H von der Kammer; C Jurincic-Winkler; R Horlbeck; K F Klippel; H U Pixberg; K H Scheit
Journal:  Urol Res       Date:  1993-05

3.  Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL.

Authors:  Stéphane Bolduc; Louis Lacombe; Alain Naud; Mireille Grégoire; Yves Fradet; Roland R Tremblay
Journal:  Can Urol Assoc J       Date:  2007-11       Impact factor: 1.862

4.  Early detection of prostate cancer local recurrence by urinary prostate-specific antigen.

Authors:  Stéphane Bolduc; Brant A Inman; Louis Lacombe; Yves Fradet; Roland R Tremblay
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

5.  Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers.

Authors:  Andreas M Luebke; Ali Attarchi-Tehrani; Jan Meiners; Claudia Hube-Magg; Dagmar S Lang; Martina Kluth; Maria Christina Tsourlakis; Sarah Minner; Ronald Simon; Guido Sauter; Franziska Büscheck; Frank Jacobsen; Andrea Hinsch; Stefan Steurer; Thorsten Schlomm; Hartwig Huland; Markus Graefen; Alexander Haese; Hans Heinzer; Till S Clauditz; Eike Burandt; Waldemar Wilczak; Doris Höflmayer
Journal:  Cancer Biol Med       Date:  2019-05       Impact factor: 4.248

Review 6.  Approaches to urinary detection of prostate cancer.

Authors:  Jillian N Eskra; Daniel Rabizadeh; Christian P Pavlovich; William J Catalona; Jun Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-01-17       Impact factor: 5.554

7.  Massively parallel sequencing of human urinary exosome/microvesicle RNA reveals a predominance of non-coding RNA.

Authors:  Kevin C Miranda; Daniel T Bond; Joshua Z Levin; Xian Adiconis; Andrey Sivachenko; Carsten Russ; Dennis Brown; Chad Nusbaum; Leileata M Russo
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.